Hypercortisolism Common in Patients with Resistant Hypertension

Why It Matters

Identifying hidden cortisol excess enables targeted referrals and therapies, potentially lowering cardiovascular complications and opening a market for diagnostic and treatment solutions.

Key Takeaways

• 27.3% of resistant hypertension patients had hypercortisolism.
• Adrenal nodules found in 24.3% of hypercortisolism cases.
• Primary hyperaldosteronism present in 21.5% of cohort.
• Screening recommended for both hypercortisolism and hyperaldosteronism.
• Patients with hypercortisolism showed higher cardiovascular risk markers.

Pulse Analysis

The MOMENTUM trial shines a light on a previously under‑appreciated endocrine driver of resistant hypertension. By systematically applying dexamethasone suppression testing to over a thousand patients, investigators uncovered a 27% prevalence of endogenous hypercortisolism—far higher than the textbook expectation of rare Cushing‑type presentations. This prevalence, coupled with a notable overlap of primary hyperaldosteronism, suggests that hormonal dysregulation is a common, yet silent, contributor to blood‑pressure treatment failure, prompting a reevaluation of current hypertension guidelines.

For clinicians, the data translate into an actionable screening imperative. Routine cortisol and aldosterone panels can be integrated into the work‑up of patients who remain hypertensive despite three or more agents, enabling early endocrinology referral and, when appropriate, adrenal imaging or surgical intervention. Early detection may curb downstream costs associated with cardiovascular events, chronic kidney disease progression, and hospitalizations. Diagnostic firms stand to benefit from increased demand for high‑sensitivity assays, while pharmaceutical companies developing cortisol antagonists or mineralocorticoid receptor blockers could see expanded indications.

Looking ahead, the study’s industry funding by Corcept Therapeutics underscores a growing commercial interest in targeting cortisol pathways. Ongoing research will likely explore whether pharmacologic cortisol blockade improves outcomes in resistant hypertension, potentially creating a new therapeutic niche. As health systems adopt broader endocrine screening, the convergence of clinical insight, diagnostic innovation, and targeted therapy promises to reshape management of a condition that affects millions of Americans.